favipiravir / Generic mfg. - LARVOL DELTA

Prolonged cytopenias after BCMA CAR‑T are associated with impaired endogenous T cell recovery characterized by decreased CD8+ T cell diversity (ASH 2025) - "We previously reported that prolongedcytopenias beyond 100 days are associated with persistently elevated inflammatory markers and serveas an early surrogate for reduced long-term survival (Avigan et al., Clin Cancer Res 2025). Despitedifferences in T cell expansion and clonality, over 88% of functional TCR sequences across both groupshad unknown antigenic targets, and our current efforts are aimed at defining the antigenic specificity andfunctional role of these expanded T cell populations.We demonstrated in two independent cilta-cel cohorts that prolonged cytopenias after CAR-T areassociated with impaired endogenous T cell recovery characterized by clonal expansion and diminisheddiversity of CAR-negative CD8+ T cells. These findings support the hypothesis that disruptions in native Tcell recovery after lymphodepletion and CAR-T infusion may promote hematologic toxicity and serve asan early marker for immune dysregulation associated with poor outcomes."

IO biomarker • Hematological Malignancies • Multiple Myeloma • CD4 • CD8

Longitudinal [18F]FDG-PET/CT as a Prognostic Tool for Influenza-Induced Lung Inflammation and Therapy Response in Mice (APSR 2025) - "Methods : Immunocompetent mice were intranasally inoculated with a lethal dose of influenza A virus (H1N1 Puerto Rico|8|34 strain) and subsequently treated with either antiviral agents (baloxavir or favipiravir) or vehicle control. Conclusion : Lung [18F]FDG uptake is a non-invasive imaging biomarker of pulmonary inflammation in influenza, providing early insights into antiviral treatment efficacy. By quantifying inflammatory responses, [18F]FDG-PET offers a valuable tool for rapid preclinical assessment of novel or repurposed influenza therapeutics, potentially acceleration drug development."

FDG PET • Preclinical • Infectious Disease • Inflammation • Influenza • Pneumonia • Pulmonary Disease • Respiratory Diseases

Genetic determinants of efficacy of antiviral drugs revealed by genome-wide CRISPR screens. (PubMed, Antiviral Res) - "For ribavirin, adenosine kinase (ADK) and adenylsuccinate synthase (ADSS) were critical for nucleotide metabolism and bioactivation. Remdesivir uptake and activation depended on the transporter SLC29A3 and phosphoamidase HINT1, whereas favipiravir resistance was linked to NT5C2-mediated dephosphorylation. Viral replication assays in Huh7 cells validated that knockout of SLC29A3, HINT1, or NT5C2 significantly altered antiviral efficacy. This study delineates the genetic network governing nucleotide analog response, providing mechanistic insights and potential biomarkers for personalized antiviral therapy."

Journal • Hematological Malignancies • Lymphoma • Oncology • HINT1 • NT5C2

WITHDRAWN Longitudinal 18F-FDG-PET/CT as a Prognostic Tool for Influenza-induced Lung Inflammation and Therapy Response in Mice (ASTMH 2025) - "Immunocompetent mice were infected with a lethal dose of influenza A /H1N1 PR8 and subsequently treated with either antiviral agents (baloxavir or favipiravir) or vehicle control. Most importantly, lung FDG correlates with inflammatory markers in the lung but not with viral burden in the tissue, confirming that lung FDG uptake reflects the inflammatory processes triggered by influenza and the reduction of inflammation resulting from effective treatment. By quantifying inflammatory responses, FDG-PET offers a valuable tool for rapid preclinical assessment of novel or repurposed influenza therapeutics, potentially acceleration drug development."

FDG PET • Preclinical • Infectious Disease • Inflammation • Influenza • Pneumonia • Pulmonary Disease • Respiratory Diseases

Safety Profile of COVID-19 Medication in Patients with CKD: Renal and Hepatic Dysfunction Associated with Antiviral and Tocilizumab Use, a Single-Centre Experience (KIDNEY WEEK 2025) - "Methods We conducted a retrospective study on 1425 COVID-19-infected patients, who received anti-viral therapy, i.e., Favipiravir, lopinavir-Ritonavir, Remdesivir and tocilizumab. Conclusion CKD patients had a significantly higher incidence of renal function deterioration and an increase in AST. Nevertheless, these abnormal lab parameters must be considered with other risk factors, associated with severe covid-19-infection, thus COVID medicine shouldn't be denied to CKD patients"

Clinical • Chronic Kidney Disease • Hepatology • Infectious Disease • Liver Failure • Nephrology • Novel Coronavirus Disease • Renal Disease

Carbon nanocone oxide-mediated controlled interaction to increase Favipiravir's bioavailability: An extensive in silico research. (PubMed, Comput Biol Chem) - "The drug-carrier interaction generated fluorescence quenching in PET, which also gave a pictorial description of the unique excited states from 1 to 10. The results collectively indicate the therapeutic potential of the ONC carrier as a favipiravir carrier for managing viral disease."

Journal • Infectious Disease

Uncovering potent natural phytochemicals targeting SARS-COV-2 spike protein variants: molecular dynamics insights. (PubMed, Sci Rep) - "This study evaluated 20 phytocompounds and four approved antiviral drugs, Remdesivir, Favipiravir, Hydroxychloroquine, and Ivermectin, against nine SARS-CoV-2 spike glycoprotein structures, including five wild-type and four variants (Alpha, Beta, Delta, and Omicron)...In contrast, ursolic acid and ivermectin showed unstable binding and higher structural fluctuations during simulation. Overall, the study highlights betulinic acid and β-sitosterol as presumptive SARS-CoV-2 inhibitors, warranting further experimental validation through in vitro and in vivo studies to confirm their therapeutic potential."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Duffy-Null Status and Delayed Neutrophil Engraftment in Autologous Hematopoietic Transplantation: A Call for Awareness (AABB 2025) - "These findings are consistent with prior work (Avigan et al., Blood Advances , 2025), which demonstrated delayed ANC recovery in Duffy-null patients post–CAR-T therapy without adverse clinical outcomes... Duffy-null patients exhibit a modest, non-harmful delay in neutrophil engraftment post-AHCT. Although these patients run similar risk for post-transplantation complications of neutropenia, they do not appear to be at greater risk based upon the slower ANC recovery. Given this physiologic variation, rigid adherence to conventional ANC-based criteria may unjustifiably stratify this population into a higher-risk category."

IO biomarker • Neutropenia • Transplantation

Six recent cases of severe fever with thrombocytopenia syndrome during the 2024 - 2025 in Kochi, Japan: A possible surge and clinical clue for early recognition. (PubMed, IJID Reg) - "Favipiravir was administered in all cases, with five recoveries...In endemic and warm-climate regions, SFTS should be suspected year-round. Key clinical features, including cat exposure, thrombocytopenia, and a slight elevation of serum C-reactive protein, may aid early diagnosis even in the absence of tick bite history."

Journal • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Infectious Disease • Thrombocytopenia • CRP

Repurposing Metal-Based Therapeutics for Human Metapneumovirus (HMPV): An Integrative Computational Approach. (PubMed, Bioinorg Chem Appl) - "Top-ranked compounds-Auranofin, silver sulfadiazine, and gallium nitrate-exhibited superior binding affinities (ΔG_binding: -68.5 to -62.7 kcal/mol), stable protein-ligand complexes (RMSD: 2.1-2.4 Å), and consistent interaction profiles when benchmarked against known antivirals ribavirin and favipiravir. Furthermore, ADMET predictions revealed acceptable oral bioavailability, low predicted toxicity, and renal clearance profiles, though known risks such as gallium accumulation were acknowledged. This integrative study highlights the potential of repurposed metallodrugs as novel anti-HMPV agents, offering a rational and cost-effective path toward therapeutic advancement."

Journal

Exploration of African natural products as VP35 inhibitors to combat Marburg virus infection: Molecular docking, molecular dynamics, and quantum mechanical computations. (PubMed, PLoS One) - "Compared to galidesivir and favipiravir, reference inhibitors, the estimated MM/GBSA binding energies of the identified ANPs with VP35 were about two times lower than galidesivir and favipiravir. These results highlighted the efficacy of computational methods in recognizing putative VP35 inhibitors, providing promising avenues for additional experimental research and prospective curative advancement toward MBV."

Journal • Hematological Disorders • Infectious Disease

Favipiravir as a potent inhibitor of Newcastle disease virus: in ovo efficacy, dose-dependent toxicity, and molecular insights into RNA polymerase inhibition. (PubMed, Vet World) - "These findings establish favipiravir as a promising antiviral candidate for ND virus control and potentially other RNA viruses of veterinary and One Health importance. Further in vivo and field-based studies are warranted to validate its safety, optimize dosing regimens, and evaluate large-scale applicability in poultry production."

Journal

Efficacy of favipiravir treatment for patients with severe fever with thrombocytopenia syndrome assessed with a historical control. (PubMed, Antimicrob Agents Chemother) - "Ferritin levels associated with hemophagocytosis severity were significantly different between the FPV and BSC groups on Days 3 to 9 after matching. No concerning serious adverse events were observed in the FPV group.This interventional study has been registered with the Japan Registry of Clinical Trials as jRCT2080223816."

Journal • Hematological Disorders • Infectious Disease • Thrombocytopenia

Antiviral strategies against H5N1: current options and emerging therapeutics. (PubMed, Infection) - "This article provides a comprehensive, up-to-date overview of antiviral agents with established or investigational activity against H5N1, including both globally approved drugs and regionally licensed compounds, such as arbidol and triazavirin in Russia and laninamivir and favipiravir in Japan...The recent regulatory approvals of onradivir, suraxavir marboxil, and ZX-7101A in China are highlighted, along with emerging antivirals in advanced development...Challenges persist around resistance monitoring, access to novel therapies, and regulatory harmonization. Expanding the antiviral armamentarium through accelerated evaluation and integration of both traditional and innovative compounds will be essential to pandemic preparedness and effective H5N1 outbreak response."

Journal • Review • Infectious Disease • Influenza • Respiratory Diseases

Synthetic genomics-based generation of the tick-borne encephalitis virus Siberian subtype prototype strain and E51K-attenuated variant for vaccine development and antiviral screening. (PubMed, Virol Sin) - "Using this reporter system, we demonstrated that favipiravir possesses antiviral activity against TBEV, with inhibitory concentrations within a pharmacologically relevant range. In conclusion, synthetic genomics enabled the generation of a reference TBEV strain to replenish Kazakhstan's collections. The E51K mutation enhances viral replication in vitro while attenuating pathogenicity in vivo, and the derived reporter virus is suitable for antiviral compound screening."

Journal • CNS Disorders

First therapeutic drug monitoring of experimental favipiravir in Borna disease virus 1 (BoDV-1) encephalitis patients reveals significant gaps in antiviral treatment: a pilot investigation. (PubMed, Eur J Med Res) - "In conclusion, monitoring experimental FPV therapy in BoDV-1 encephalitis is feasible and should be performed continuously. Future prospective in-depth (multicenter) studies should include more patients and focus on dose-finding, dose-response relationships, and define a therapeutic index to improve outcomes of this so far nearly uniformly fatal disease."

Journal • CNS Disorders

Conserved Filovirus Proteins as Targets of Broad-Spectrum Antivirals. (PubMed, bioRxiv) - "Conserved filovirus sites targeted for broad-spectrum antivirals.Structural modeling identifies key antiviral binding sites.Viral internal proteins are crucial targets for inhibition.Remdesivir validates conserved polymerase as a druggable target.Study highlights need for pan-filovirus drug screening."

Journal • Ebola Virus Disease • Hematological Disorders • Infectious Disease

Recent Advances in Therapeutics for Severe Fever with Thrombocytopenia Syndrome Virus. (PubMed, Viruses) - "The nucleotide analogues (favipiravir, 4'-fluorouridine diphosphate prodrug VV261) have shown clinical potential. Calcium channel blockers (nifedipine, etc.) block virus invasion by inhibiting calcium influx...In addition, the low bioavailability of small-molecule drugs, the obstacles to industrial-scale production of antibody-based therapies, and the lack of Phase III clinical evidence severely restrict their clinical translation. Future research should focus on exploring viral replication mechanisms, developing drugs against key viral proteins, and designing multi-target combination therapies and novel drug delivery systems."

Journal • Review • Hematological Disorders • Thrombocytopenia

In Vivo Efficacy of a Broad-Spectrum Antiviral Combination Against Yellow Fever in a Hamster Model. (PubMed, Pathogens) - "Herein, we describe the evaluation of 6-MMPr, a de-novo-purine-nucleotide biosynthesis inhibitor, as a potentiator for enhanced activity of the broad-spectrum antiviral drug favipiravir in a hamster model of yellow fever...The initiation of treatment two days after virus challenge was also effective in improving survival when compared with monotherapy. Our results demonstrate the safety and efficacy of such a combination either as a preventive or delayed treatment."

Journal • Preclinical

Development and Validation of a Novel Isocratic RP-HPLC Method Using AQbD Approach for the Quantification of Favipiravir. (PubMed, Eur J Pharm Sci) - "AQbD is a useful tool to replace existing traditional methods for the optimization of a green, validated RP-HPLC method, for the routine analysis and quality control of FAV."

Journal

Delayed Hematologic Recovery After BCMA CAR-T Is Associated with Progressive Loss of Endogenous T Cell Diversity After CAR-T Infusion (IMS 2025) - "We previously reported (Avigan et al, ASH 2024 abstract 3329) that patients with prolonged cytopenias beyond day 100 have decreased survival and persistently increased inflammatory markers after CAR-T...We therefore hypothesized that patients with delayed hematologic recovery after CAR-T would show a distinct endogenous T cell recovery pattern, which may contribute to ongoing hematotoxicity. We reviewed patients treated with cilta-cel with available NGS of their T cell receptor (TCR) repertoire within 2 years and prior to relapse... Patients with delayed hematologic recovery after CAR-T showed increased TCR clonal dominance and decreased diversity in endogenous T cell populations, with a marked disruption in diversity after 6 months. Our current efforts are aimed at understanding and characterizing the role of native T cell diversity in driving inflammatory dysregulation, hematologic toxicity, and disease response after CAR-T."

IO biomarker • Hematological Disorders • Hematological Malignancies • Multiple Myeloma

An orally available 4'-fluorouridine prodrug inhibits SFTSV and LCMV infection. (PubMed, J Virol) - "In lethal rodent models, once-daily oral administration of VV251 at low doses (10 mg/kg for SFTSV; 1 mg/kg for LCMV) achieves complete protection (100% survival), matching the efficacy of T-705 at 300 mg/kg...Here, we report that VV251 hydrochloride salt (VV251), an optimized oral prodrug derivative of 4'-fluorouridine (4'-FlU, EIDD-2794), shows significant efficacy against severe fever with thrombocytopenia syndrome virus and lymphocytic choriomeningitis virus infections, with inhibitory activity in cell culture and protective effects in lethal animal models. Building on the established broad-spectrum antiviral activity of 4'-FlU against multiple high-consequence pathogens (including severe acute respiratory syndrome coronavirus 2, respiratory syncytial virus, Lassa virus, and Junin virus), VV251 emerges as a promising next-generation oral antiviral candidate, offering an orally available therapeutic option to combat these formidable pathogens."

Journal • CNS Disorders • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Thrombocytopenia

AGILE (Early Phase Platform Trial for COVID-19) (clinicaltrials.gov) - P1/2 | N=600 | Recruiting | Sponsor: University of Liverpool | Active, not recruiting ➔ Recruiting | Trial completion date: Jul 2025 ➔ Oct 2026 | Trial primary completion date: Jul 2025 ➔ Oct 2026

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Increasing Occurrence of Marburg Virus Outbreaks in Africa: Risk Assessment for Public Health. (PubMed, Microb Biotechnol) - "Compounds included galidesivir, an adenosine nucleoside analogue; favipiravir, a synthetic guanine base analog; remdesivir, an injectable; and obeldesivir, an oral prodrug which are intracellularly metabolised to an adenosine triphosphate nucleotide analog; small interfering RNA drugs that target short segments of the MARV nucleoprotein NP mRNA; and a human neutralising monoclonal antibody directed against MARV glycoprotein. The African CDC has attributed an upper tier risk attribution to MVD when comparing 18 pathogens. For the moment, the short human MARV infection chains make large international outbreaks unlikely, but viral genome analysis in future outbreaks for transmission mutants is warranted."

Journal • Review • Infectious Disease

Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model. (PubMed, J Antimicrob Chemother) - "Placental transfer was high for the nucleoside analogue favipiravir, while it was low for molnupiravir and low for the protease inhibitor nirmatrelvir but increased by ritonavir. Clinical data are required to confirm the placental transfer and determine the safety of COVID antivirals in pregnancy."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease